Genelux (GNLX) Interest Expenses (2022 - 2026)
Genelux's (GNLX) quarterly Interest Expenses came in at $336000.0 in Q1 2026, up 314.81% year-on-year from $81000.0 in Q1 2025, and down 99.57% quarter-over-quarter from $78.5 million in Q4 2025.
Genelux (GNLX) Interest Expenses (2022 - 2026) Analysis & Trends
Genelux's Interest Expenses history runs 5 years deep, the most recent figure standing at $336000.0 for Q1 2026.
- On a quarterly basis, Interest Expenses rose 314.81% year-over-year to $336000.0 in Q1 2026; TTM through Mar 2026 was $336000.0, a 269.7% increase from a year earlier, with the FY2025 full-year figure at $78.5 million, up 29.32% from the prior year.
- Interest Expenses eased to $336000.0 in Q1 2026 per GNLX's latest filing, from $78.5 million in the prior quarter.
- Across five years, Interest Expenses topped out at $111.8 million in Q2 2023 and bottomed at -$359000.0 in Q4 2023.
- The 5-year median for Interest Expenses is $336000.0 (2026), against an average of $18.2 million.
- Across the five-year window, Interest Expenses slumped 1789.47% in 2023 and jumped 89328.41% in 2025, its largest moves.
- Year by year, Interest Expenses stood at -$19000.0 in 2022, then slumped by 1789.47% to -$359000.0 in 2023, then jumped by 75.49% to -$88000.0 in 2024, then soared by 89328.41% to $78.5 million in 2025, then tumbled by 99.57% to $336000.0 in 2026.
- Per Business Quant, the three latest GNLX Interest Expenses figures stand at $336000.0 (Q1 2026), $78.5 million (Q4 2025), and $3.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - | -42,141.15 |
| 2 | Nanobiotix | 1,935.05 Bn | 1,934.98 Bn | - | - |
| 3 | Akari Therapeutics | 1,023.69 Bn | 1,023.69 Bn | - | 100,000.00 |
| 4 | BeOne Medicines | 468.59 Bn | 463.80 Bn | 1.35 Bn | 32.89 Mn |
| 5 | Vertex Pharmaceuticals | 123.01 Bn | 115.76 Bn | 2.59 Bn | 420.30 Mn |
| 6 | Regeneron Pharmaceuticals | 70.29 Bn | 61.53 Bn | 3.31 Bn | 28.30 Mn |
| 7 | Belite Bio | 63.33 Bn | 63.33 Bn | - | - |
| 8 | Argenx Se | 55.70 Bn | 50.52 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.79 Bn | 34.78 Bn | 959.66 Mn | 69.29 Mn |
| 10 | Genelux | 129.36 Mn | 129.36 Mn | - | 336,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 336,000.00 |
| Mar 31, 2026 | 336,000.00 |
| Dec 31, 2025 | 78.52 Mn |
| Dec 31, 2025 | 78.52 Mn |
| Sep 30, 2025 | 3.26 Mn |
| Sep 30, 2025 | 3.26 Mn |
| Jun 30, 2025 | 493,000.00 |
| Jun 30, 2025 | 493,000.00 |
| Mar 31, 2025 | 81,000.00 |
| Mar 31, 2025 | 81,000.00 |
| Dec 31, 2024 | -88,000.00 |
| Dec 31, 2024 | -88,000.00 |
| Sep 30, 2024 | 168,000.00 |
| Sep 30, 2024 | 168,000.00 |
| Mar 31, 2024 | 1.65 Mn |
| Mar 31, 2024 | 1.65 Mn |
| Dec 31, 2023 | -359,000.00 |
| Dec 31, 2023 | -359,000.00 |
| Sep 30, 2023 | 73.44 Mn |
| Sep 30, 2023 | 73.44 Mn |